Cramer’s Morning Thoughts: 20 Stocks to Watch

Page 4 of 19

16. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Number of Hedge Fund Investors: 57

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) was downgraded by Leerink to “market perform” after a preliminary ruling against its Eylea 2mg biosimilar. However, Truist analysts called the selloff on this news an overreaction.

“Leerink analysts downgraded Regeneron to a market perform hold after a negative Eylea 2mg biosimilar preliminary injunction ruling. Truist called the selling on this news an overreaction.”

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is an appealing investment option, thanks to its strong financial performance and innovative range of therapies. In its Q2 2024 earnings report, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced total revenue of $2.7 billion, marking a 15% increase from the previous year, along with a net income of $1.2 billion, primarily driven by robust sales of EYLEA, its leading treatment for retinal diseases.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) has a solid pipeline of promising drug candidates focused on oncology, ophthalmology, and immunology, addressing important medical needs. Strategic partnerships, such as its collaboration with Sanofi, enhance Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)’s research capabilities and speed up drug development.

Recently, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) received regulatory approval for a new use of EYLEA, broadening its market potential, and positive trial results for other therapies may lead to more product launches soon. With a strong reputation and commitment to innovation, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is well-positioned for growth in the competitive biopharmaceutical market, making it an attractive choice for investors.

Page 4 of 19